{"schema_version":"secwatch.filing_event.v1","accession":"0001851734-22-000581","form_type":"8-K","ticker":"NAGE","cik":"0001386570","company_name":"Niagen Bioscience, Inc.","filed_at":"2022-10-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.404753+00:00","generated_at":"2026-06-23T05:53:01.100156+00:00","sec_items":["1.01","1.02","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"ChromaDex forms China JV for Tru Niagen, sells $3.1M stock to insiders at $1.25/sh","bullets":["Taikuk invests $1M for 11% non-voting stake in JV to commercialize Tru Niagen in China; Blue Hat registration required within 24 months.","Prior Term Sheet with Crystal Lake and Pioneer Idea terminated; new structure approved by Audit Committee.","Company sells 2.48M shares at $1.25 for $3.1M to existing holders including CEO Robert Fried; closing expected Oct 7, 2022.","Shares unregistered, sold under Rule 506; Registration Rights Agreement provides for future resale registration."],"urls":{"canonical":"https://secwatch.observer/filing/0001851734-22-000581","json":"https://secwatch.observer/filing/0001851734-22-000581.json","markdown":"https://secwatch.observer/filing/0001851734-22-000581.md","text":"https://secwatch.observer/filing/0001851734-22-000581.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1386570/000185173422000581/0001851734-22-000581-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1386570/000185173422000581/cdxc20220930_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T05:53:01.100156+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}